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Abstract 11 
Introduction: The purpose of this study was to investigate the diagnostic 12 
accuracy of cardiac 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the 13 
diagnosis of Parkinson’s disease (PD), especially in the early stages.  14 
Methods: We investigated 600 patients who underwent cardiac 123I-MIBG 15 
scintigraphy to diagnose their parkinsonism and/or cognitive impairment. Of 16 
600 research subjects, 272 patients were clinically diagnosed with PD. MIBG 17 
 3 
uptake was compared between patients with PD and other diseases. 1 
Furthermore, the sensitivity and specificity of cardiac 123I-MIBG scintigraphy to 2 
diagnose PD was estimated by disease duration (less than 3 years: early group 3 
vs. over 3 years: late group). We also assessed the relationship between MIBG 4 
uptake and Hoehn & Yahr stage. 5 
Results: MIBG uptakes of PD patients were significantly decreased compared 6 
with those of other diseases except dementia with Lewy bodies and pure 7 
autonomic failure (p < 0.05 for all). In the early group, the sensitivity and 8 
specificity of the delayed heart to mediastinum (H/M) ratio were 68.7% and 9 
91.7%, respectively, while in the late group, the sensitivity was 86.3% and the 10 
specificity was 74.0%. In addition, the early and delayed H/M ratios were 11 
decreased with higher Hoehn & Yahr stages in PD patients. 12 
Conclusion: Our findings demonstrated that cardiac 123I-MIBG scintigraphy had 13 
sufficient diagnostic accuracy to detect the early phase of PD. Indeed, this 14 
study of a large number of patients provides further external validation that 15 
MIBG has diagnostic ability to distinguish PD from atypical parkinsonism. 16 
 17 
 4 
1. Introduction 1 
 2 
Parkinson’s disease (PD) is usually diagnosed based on clinical criteria such as 3 
the UK Parkinson’s Disease Society Brain Bank Research Center 4 
(UKPDSBRC) diagnostic clinical criteria, which are used worldwide by experts 5 
in the area of movement disorders [1]. However, a previous study reported that 6 
the pooled diagnostic accuracy of PD based on these criteria was just 82.7%, 7 
suggesting suboptimal accuracy in the clinical diagnosis of PD [2]. Furthermore, 8 
gold standard clinical tests for diagnosing PD have not yet been established. 9 
Thus, it is still challenging to diagnose PD clinically, particularly during its early 10 
phase. 11 
123I-metaiodobenzylguanidine (MIBG) is an analog of noradrenaline, and 12 
cardiac 123I-MIBG scintigraphy has mainly been used as a radionuclide imaging 13 
tool to evaluate myocardial postganglionic sympathetic innervation [3]. A 14 
number of studies have shown that MIBG uptake is decreased in PD, dementia 15 
with Lewy bodies (DLB), and pure autonomic failure (PAF), which are 16 
collectively known as Lewy body diseases (LBDs) [3-5]. The low uptake of 17 
 5 
MIBG in these diseases is presumably due to an accumulation of Lewy bodies 1 
in the peripheral sympathetic nervous system among patients with LBDs [6]. 2 
Previous studies have reported that cardiac 123I-MIBG scintigraphy can be used 3 
to differentiate LBDs from atypical parkinsonism or diseases with cognitive 4 
impairments, such as Alzheimer’s disease (AD) [3, 4]. However, the diagnostic 5 
accuracy of cardiac 123I-MIBG scintigraphy in diagnosing early-phase PD, and 6 
the association of MIBG uptake with PD symptoms and severity, have not been 7 
fully established [7-9].  8 
The aim of this study was to investigate the usefulness of cardiac 123I-MIBG 9 
scintigraphy in the diagnosis of early-phase PD in a large-scale observational 10 
study of Japanese patients. We also aimed to investigate the associations of 11 
MIBG uptake with Hoehn & Yahr (H-Y) staging and detailed motor and 12 
non-motor symptoms in PD patients.  13 
 14 
2. Materials and methods 15 
 16 
2.1. Study design and subjects 17 
 6 
 1 
This was a single-center, retrospective cohort study. We enrolled 816 2 
consecutive patients with parkinsonism and/or cognitive impairment at their first 3 
visits or their follow-up periods and performed cardiac 123I-MIBG scintigraphy 4 
on these patients to support diagnoses of PD or DLB, which can be clinically 5 
misdiagnosed as atypical parkinsonism (e.g., multiple system atrophy [MSA], 6 
progressive supranuclear palsy [PSP], and corticobasal degeneration [CBD]) or 7 
other cognitive disorders (e.g., AD). The study was performed at the 8 
Department of Neurology in the Fukuoka University Hospital between January 9 
2005 and May 2016. After excluding patients with a history of diabetes mellitus 10 
(n = 101) or cardiac disease (n = 27), and those on tricyclic or tetracyclic 11 
antidepressants, selective serotonin reuptake inhibitors (SSRI), or 12 
antipsychotics (due to their possible influence on MIBG uptake [10]; n = 91), a 13 
total of 600 subjects were included in this study. 14 
The current study involved two sets of analyses: (1) In 600 patients, MIBG 15 
uptake was compared across different types of diseases, based on final 16 
diagnosis (see section 2.2 for diagnostic criteria). (2) In the 272 patients who 17 
 7 
were diagnosed with PD, we analyzed the correlation between MIBG uptake 1 
and initial motor symptoms, motor and non-motor symptoms at the time of the 2 
MIBG test, and the staging of the motor symptoms. Patient demographics and 3 
clinical information were retrospectively gathered from clinical notes. 4 
The study was approved by the Institutional Review Board–Independent Ethics 5 
Committee of Fukuoka University (16-9-11). 6 
 7 
2.2. Definition of diagnosis 8 
 9 
A diagnosis of probable PD was made based on UKPDSBRC diagnostic clinical 10 
criteria [1], and the other diseases were diagnosed based on widely accepted 11 
criteria [11-15]. Two patients who had an apparent family history of 12 
parkinsonism were classified as having unclassified parkinsonian syndrome, 13 
while 114 patients who did not fulfill any set of criteria were classified as 14 
undetermined. We evaluated the initial symptoms from medical records. The 15 
initial motor symptoms were defined as follows: (1) gait disturbance: stooped 16 
posture with short steppage gait and/or freezing of gait; (2) rigidity: complaints 17 
 8 
of stiffness in combination with resistance to passive movement in extremities; 1 
(3) tremor: symptoms of uncontrolled shaking in extremities and/or the jaw; and 2 
(4) bradykinesia: slowness of spontaneous movement and/or facial expression. 3 
Motor symptoms at the time of the MIBG test were evaluated based on medical 4 
history and standardized neurological examinations carried out by several 5 
neurologists (MK, TM, SF, JT, YT). Non-motor symptoms at the time of the 6 
MIBG test were also defined based on medical history and/or physical findings, 7 
and were classified as follows: (1) dementia and mild cognitive impairments: 8 
symptoms of memory problems that yielded an apparent disturbance of daily 9 
life, and/or Mini-Mental State Examination (MMSE) scores of < 20 points [16]; 10 
(2) orthostatic hypotension: subjectively, with complaints of lightheadedness or 11 
blurred vision in the upright posture and/or a decrease in systolic blood 12 
pressure of at least 20 mmHg during the head-up tilt test [17]; (3) depression: 13 
depressive symptoms and/or current/past use of anti-depressants; (4) 14 
constipation: bowel movement of twice a week or less and/or a chronic use of 15 
laxatives; (5) urinary disturbance: frequent urination, nocturia, and/or chronic 16 
use of drugs for the treatment of these symptoms; (6) hallucination and 17 
 9 
delusion: apparent episodes of vivid and visual hallucinations and/or a 1 
delusional disorder pointed out by others; (7) REM sleep behavior disorder 2 
(RBD): symptoms of arm/leg movement, and/or shouting, speaking, or laughing 3 
loudly during sleep that was reported by a bed-partner of a patient [18]; and (8) 4 
other: non-motor symptoms that did not fit into categories (1)–(7). We defined 5 
PD severity according to the H-Y stage at the time of the MIBG test [19]. We 6 
also defined disease duration as the time from onset of first symptoms to MIBG 7 
scintigraphy, while follow-up time was defined as the time from MIBG 8 
scintigraphy to final diagnosis. 9 
 10 
2.3. Cardiac 123I-MIBG scintigraphy 11 
 12 
Cardiac 123I-MIBG scintigraphy was performed using the same protocol 13 
throughout this study. 111 MBq of 123I-MIBG (FUJIFILM RI Pharma Co., Ltd., 14 
Tokyo, Japan) was injected intravenously. Early and delayed images were 15 
obtained after 15 min and 180 min with a triple head gamma camera (PRISM 16 
3000-IRIX, Philips Healthcare, Amsterdam, Netherlands) with low-energy 17 
 10 
general all-purpose (LEGAP) collimators. The photopeak of 123I was centered at 1 
159 keV with ± 10% energy window, and all data were collected for 5 min with a 2 
512 × 512 matrix. Regions of interest (ROIs) were manually drawn around the 3 
heart (H) and a square (2 × 2 cm) ROI was set on the upper mediastinum (M) 4 
on a planar image. Tracer uptake was used to calculate the early (15 min) and 5 
delayed (180 min) H/M ratio. We set a cut-off point of 2.0 for both the early and 6 
delayed H/M ratios [20, 21]. 7 
  8 
2.4. Statistical analysis 9 
 10 
All data were presented as mean ± SD or as n (%). In the first set of analyses, 11 
we compared the mean H/M ratio values across different types of diseases 12 
using one-way analysis of variance (ANOVA) and analysis of covariance 13 
(ANCOVA), including sex and age at the time of the MIBG test as covariates. In 14 
the second set of analyses, H/M ratios in the PD group were compared 15 
according to the presence of initial symptoms or of motor/non-motor symptoms 16 
at the time of the MIBG test, and according to H-Y stages, using ANCOVA with 17 
 11 
adjustments for sex and age at the time of the MIBG test. Finally, we calculated 1 
the sensitivity, specificity and global accuracy of the MIBG test in detecting PD. 2 
Statistical analyses were performed using SAS software (version 9.4). A 3 
significant difference was defined as p < 0.05. 4 
 5 
3. Results 6 
 7 
3.1. Basic characteristics and H/M ratio according to final diagnosis 8 
 9 
Basic characteristics of all study participants are summarized in Table 1. Of the 10 
600 research subjects, 272 were male (45.3%). The mean age at onset and 11 
age at the time of the MIBG test were 65.2 ± 12.6 and 69.1 ± 11.4 years, 12 
respectively. The mean disease duration and follow-up time were 3.8 ± 5.0 13 
years and 2.3 ± 2.7 years, respectively. The results of the H/M ratio comparison 14 
between PD and other diseases (according to final diagnosis) are shown in 15 
Figure 1. Compared with PD patients, the early and delayed H/M ratios of all 16 
patients were significantly higher than those of all other diseases except for 17 
 12 
DLB and PAF patients, using both ANOVA and ANCOVA analyses (ANCOVA 1 
analysis results are shown in Figure 1). 2 
 3 
3.2. Basic characteristics of PD patients 4 
 5 
Basic characteristics of PD patients are summarized in Table 2. Of the 272 PD 6 
patients, 119 (43.8%) were male. The mean age at onset and age at the time of 7 
the MIBG test were 62.2 ± 12.8 and 66.4 ± 11.8 years, respectively. The mean 8 
disease duration and follow-up time were 4.1 ± 5.1 years and 4.8 ± 3.9 years, 9 
respectively. When patients were divided by disease severity according to H-Y 10 
stages, results were as follows: H-Y 0, n = 1 (0.4%); H-Y 1, n = 52 (19.1%); H-Y 11 
2, n = 62 (22.8%); H-Y 3, n = 106 (39.0%); H-Y 4, n = 17 (6.3%); H-Y 5, n = 2 12 
(0.7%); H-Y unknown, n = 32 (11.8%). Among the 127 patients (46.7%) who 13 
had experienced tremor during the course of their illness, tremor was clinically 14 
confirmed in 56 patients (20%) by neurologists during examination at the time 15 
of the MIBG test. One hundred and sixteen patients (42.7%) were taking 16 
levodopa at the time of the MIBG test, and the mean dose of levodopa was 17 
 13 
334.5 ± 155.3 mg. Seventy-four patients (27.2%) were taking dopamine 1 
agonists at the time of the MIBG test.  2 
 3 
3.3. H/M ratio according to the clinical symptoms of PD patients 4 
 5 
Among the 272 PD patients, the early and delayed H/M ratios were significantly 6 
lower in patients with rigidity at disease onset compared with those without 7 
rigidity at disease onset (early H/M ratio: difference 0.13, 95% CI 0.01 to 0.24, p 8 
= 0.031; delayed H/M ratio: difference 0.21, 95% CI 0.06 to 0.35, p = 0.006). 9 
The delayed H/M ratio was significantly lower in patients with tremor at the time 10 
of the MIBG test compared with those without tremor at testing (difference 0.14, 11 
95% CI 0.002 to 0.28, p = 0.047). In addition, in patients with the following 12 
symptoms at the time of the MIBG test, the early and delayed H/M ratios were 13 
significantly lower compared with those without each of the following 14 
symptoms: constipation (early H/M ratio: difference 0.19, 95% CI 0.10 to 0.27, p 15 
< 0.001; delayed H/M ratio: difference 0.21, 95% CI 0.10 to 0.32, p < 0.001), 16 
urinary disturbance (early H/M ratio: difference 0.14, 95% CI 0.03 to 0.24, p = 17 
 14 
0.011; delayed H/M ratio: difference 0.17, 95% CI 0.04 to 0.31, p = 0.013), and 1 
RBD (early H/M ratio: difference 0.17, 95% CI 0.05 to 0.29, p = 0.005; delayed 2 
H/M ratio: difference 0.20, 95% CI 0.04 to 0.35, p = 0.015).  3 
 4 
3.4. H/M ratio according to the H-Y stage of PD patients 5 
 6 
Among the 272 PD patients, we classified 240 patients into four groups 7 
according to disease severity based on H-Y stage: H-Y stage 0–1 (n = 53), H-Y 8 
stage 2 (n = 62), H-Y stage 3 (n = 106) and H-Y stage 4–5 (n = 19). The 9 
remaining 32 PD patients were excluded from this analysis because their H-Y 10 
stages were undetermined. We then analyzed the correlation between H/M 11 
ratio and disease severity in these 240 PD patients. The early H/M ratio 12 
decreased with H-Y stage progression, and was significantly lower in H-Y stage 13 
3 and stage 4–5 patients compared with H-Y stage 0–1 (H-Y stage 0–1 vs. H-Y 14 
stage 3: difference 0.13, 95% CI 0.002 to 0.26, p = 0.047; H-Y stage 0–1 vs. 15 
H-Y stage 4–5: difference 0.24, 95% CI 0.03 to 0.44, p = 0.024). The delayed 16 
H/M ratio also decreased with H-Y stage progression, and was significantly 17 
 15 
lower in H-Y stage 3 and stage 4–5 patients compared with H-Y stage 0–1 (H-Y 1 
stage 0–1 vs. H-Y stage 3: difference 0.22, 95% CI 0.04 to 0.39, p = 0.015; H-Y 2 
stage 0–1 vs. H-Y stage 4–5: difference 0.44, 95% CI 0.16 to 0.71, p = 0.002) 3 
and in H-Y stage 4–5 compared with H-Y stage 2 ( H-Y stage 2 vs. H-Y stage 4 
4–5: difference 0.29, 95% CI 0.02 to 0.56, p = 0.036).  5 
 6 
3.5. Sensitivity and specificity of cardiac 123I-MIBG scintigraphy 7 
 8 
Finally, to calculate the sensitivity and specificity of the MIBG test in detecting 9 
PD, 441 patients were grouped into either PD (n = 272) or non-PD (n = 169; 33 10 
MSA, 28 PSP, 12 CBD, 10 vascular parkinsonism [VaP], 4 drug-induced 11 
parkinsonism, 10 unclassified parkinsonism, 6 essential tremor [ET], 39 12 
AD/mild cognitive impairment and 27 others) patients after excluding the other 13 
159 patients (43 DLB, 2 PAF, and 114 undetermined patients) from the 600 14 
total research subjects. The sensitivity, specificity and global accuracy of the 15 
early H/M ratio were 74.3% (95% CI: 69.1 to 79.5), 82.2% (95% CI: 76.4 to 16 
88.0) and 77.3% (95% CI: 73.4 to 81.2), and those of the delayed H/M ratio 17 
 16 
were 75.0% (95% CI: 69.9 to 80.1), 84.0% (95% CI: 78.5 to 89.5) and 78.5% 1 
(95% CI: 74.7 to 82.3), respectively. Additionally, we divided the 441 patients 2 
into two groups according to disease duration, of either less than 3 years (early 3 
group) or over 3 years (late group), and the sensitivity, specificity and global 4 
accuracy of the MIBG test were also calculated for each group. In the early 5 
group, the sensitivity, specificity and global accuracy of the early H/M ratio were 6 
64.5% (95% CI: 57.0 to 72.0), 87.5% (95% CI: 80.9 to 94.1) and 73.3% (95% 7 
CI: 67.7 to 82.9), and those of the delayed H/M ratio were 68.7% (95% CI: 61.4 8 
to 76.0), 91.7% (95% CI: 86.2 to 97.2) and 76.1% (95% CI: 70.8 to 81.4), 9 
respectively. In the late group, the sensitivity, specificity and global accuracy of 10 
the early H/M ratio were 87.2% (95% CI: 81.1 to 93.3), 75.3% (95% CI: 65.4 to 11 
85.2) and 82.6% (95% CI: 77.2 to 88.0), and those of the delayed H/M ratio 12 
were 86.3% (95% CI: 80.1 to 92.5), 74.0% (95% CI: 63.9 to 84.1) and 81.6% 13 
(95% CI: 76.1 to 87.1), respectively.        14 
 15 
4. Discussion 16 
 17 
 17 
In this large-scale study performed in present-day Japan, we demonstrated that 1 
MIBG scintigraphy was a useful tool to detect LBDs with high specificity, and 2 
particularly for early PD. Additionally, the H/M ratio decreased with disease 3 
progression in PD patients. A decrease in the H/M ratio was also observed in 4 
PD patients with constipation, urinary disturbance, or RBD. 5 
Further, our study showed that cardiac 123I-MIBG scintigraphy is beneficial for 6 
distinguishing LBDs from various movement disorders including atypical 7 
parkinsonism, vascular parkinsonism, drug-induced parkinsonism, and ET 8 
(Figure 1). Although the usefulness of MIBG scintigraphy has been 9 
demonstrated in previous reports [3, 4, 32], our study has corroborated this 10 
finding using a large number of cases. Moreover, it has not been confirmed 11 
whether cardiac 123I-MIBG scintigraphy is sufficiently accurate in the diagnosis 12 
of early PD. Recent meta-analyses showed that the sensitivity and specificity of 13 
MIBG scintigraphy (the delayed H/M ratio) were 88% and 85%, respectively, for 14 
the diagnosis of PD vs. other parkinsonisms [22], and 89.7% and 82.6%, 15 
respectively, for the diagnosis of PD vs. other neurodegenerative 16 
parkinsonisms [23]. In the latter analysis, the sensitivity and specificity to detect 17 
 18 
early PD (H-Y 1 or 2) were 94.1% and 80.2%, respectively; therefore, the 1 
authors concluded that MIBG scintigraphy may be a useful tool to distinguish 2 
early PD. Our study revealed that the specificity of the delayed H/M ratio to 3 
diagnose early-phase PD (disease duration < 3 years) was very high (91.7%), 4 
suggesting that MIBG scintigraphy can be very useful to confirm PD at its early 5 
stages. Here, we confirmed these findings and also demonstrated higher 6 
specificity of MIBG scintigraphy for diagnosis of early-phase PD compared with 7 
late-phase PD. The mechanisms underlying reduced specificity in late-phase 8 
PD are not clear, however, one explanation may involve an increase in 9 
pseudo-positive cases because H/M ratios decrease modestly in 10 
neurodegenerative diseases other than PD (e.g., MSA) in their later stages [24].  11 
Most prior studies demonstrated an association between a reduction in the H/M 12 
ratio and the progression of motor symptoms [25, 26]. Our study confirmed 13 
these findings, and clearly demonstrated that the early and delayed H/M ratios 14 
significantly decreased with disease progression, taken as H-Y stages. The 15 
association between the progression of motor symptoms and the decline in H/M 16 
ratio may reflect a parallel decline among patients with PD in motor function and 17 
 19 
autonomic function [9, 26], which is mainly evaluated by cardiac 123I-MIBG 1 
scintigraphy. 2 
Regarding the phenotype of motor symptoms, in our study, delayed H/M ratio 3 
significantly decreased in patients with tremor at MIBG testing, which is similar 4 
to the findings of Chiaravalloti et al., [27]. Contrarily, other studies have shown 5 
greater impairments in MIBG uptake with akinetic rigid type (ART) or postural 6 
instability and gait disturbance type (PIGD) than tremor dominant type (TDT) 7 
[28-30]. We also found that H/M ratios clearly decreased in patients with 8 
non-motor symptoms (such as constipation, urinary disturbance, and RBD), but 9 
did not in patients with dementia, orthostatic hypotension, depression, or 10 
hallucinations. These findings are consistent with previous studies [9, 31, 32], 11 
although several studies demonstrated reduced H/M ratios in orthostatic 12 
hypotension and dementia [9, 33]. Discrepancies in findings across different 13 
studies may be partially attributable to differences in study design, settings, 14 
participants, and assessment/definition of symptoms. 15 
In 2015, the Movement Disorder Society (MDS) has launched the MDS clinical 16 
diagnostic criteria for PD, which recommend MIBG scintigraphy for confirmation 17 
 20 
of the diagnosis [34]. It has been suggested that diagnostic accuracy of the 1 
MDS clinical diagnostic criteria is superior to that of the UKPDSBRC diagnostic 2 
clinical criteria [35]. Considering high specificity of MIBG test for diagnosis of 3 
PD observed in this study, we also support usefulness of the MDS clinical 4 
diagnostic criteria for PD. 5 
Several limitations to this study should be discussed. First, as a single-center 6 
study, there may be selection bias; however, a single-center study is also 7 
advantageous because of the uniform procedures in clinical practice and 8 
imaging tests at a single site. Second, each diagnosis has not been confirmed 9 
pathologically. Third, we could not confirm each diagnosis using MDS criteria 10 
because most participants were evaluated before the determination of this 11 
criteria. Fourth, all the demographic and clinical information were 12 
retrospectively gathered, meaning that some clinical data may have been 13 
missed. Finally, because genetic analyses were not performed, recessive PD, 14 
in which the H/M ratio is usually preserved [36, 37], may have been 15 
misdiagnosed as idiopathic PD. 16 
 21 
In conclusion, cardiac 123I-MIBG scintigraphy appears to be helpful in the 1 
confirmation of diagnosis in early PD. Previous studies have suggested that 2 
early intervention with dopamine replacement therapy can contribute to quality 3 
of life in PD patients [38, 39], earlier and more accurate PD diagnoses using 4 
cardiac 123I-MIBG scintigraphy would be helpful for patients with suspected PD 5 
who have mild symptoms. 6 
 7 
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Figure captions 1 
Figure 1 Early (A) and delayed H/M ratio (B) according to final diagnosis 2 
 3 
Solid boxes represent estimates of mean heart to mediastinum (H/M) ratio. 4 
Vertical lines represent 95% confidence intervals. Values were adjusted for sex 5 
and age at time of 123I-metaiodobenzylguanidine (MIBG) testing. * p < 0.001. 6 
PD: Parkinson’s disease, DLB: dementia with Lewy bodies, PAF: pure 7 
autonomic failure, MSA: multiple system atrophy, PSP: progressive 8 
supranuclear palsy, CBD: corticobasal degeneration, VaP: vascular 9 
parkinsonism, Drug-induced: drug-induced parkinsonism, Unclassified: 10 
unclassified parkinsonian syndrome, ET: essential tremor, AD/MCI: Alzheimer’s 11 
disease/mild cognitive impairment. 12 
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Table 1 Baseline characteristics of patients according to final diagnosis 
  
 
PD  
(n = 272) 
 
DLB  
(n = 43) 
 
PAF  
(n = 2) 
 
MSA  
(n = 33) 
 
PSP  
(n = 28) 
 
CBD  
(n = 12) 
 
VaP  
(n = 10) 
Drug- 
induced  
(n = 4) 
Unclassified  
parkinsonian  
syndrome (n = 10)  
 
ET  
(n = 6) 
 
AD/MCI  
(n = 39) 
 
Others 
 (n = 27) 
 
Undetermined 
 (n = 114) 
Male 
119 
(43.8%) 
17 
(39.5%) 
1 
(50.0%) 
13 
(39.4%) 
19 
(67.9%) 
6 
(50.0%) 
7 
(70.0%) 
0 
(0.0%) 
4 
(40.0%) 
4 
(66.7%) 
14 
(36.0%) 
15 
(55.6%) 
53 
(46.5%) 
Age at onset  
(years)  
62.2  
(12.8) 
72.3 
(9.0) 
76.0  
(14.1) 
60.9 
 (9.8) 
67.6  
(6.5) 
71.9  
(5.8) 
74.9  
(9.0) 
59.3  
(10.9) 
68.4  
(5.5) 
62.8  
(16.7) 
70.9  
(9.6) 
58.3 
 (19.7) 
67.9  
(12.2) 
Age at MIBG test 
(years)  
66.4 
(11.8) 
76.5 
(6.9) 
82.0 
(5.7) 
63.6 
(9.6) 
71.8 
(6.5) 
73.8 
(6.1) 
78.7 
(7.6) 
67.0 
(10.7) 
72.9 
(7.1) 
70.3 
(10.7) 
74.1 
(9.8) 
64.5 
(13.3) 
71.3 
(11.1) 
Disease duration 
(years)  
4.1 
(5.1) 
4.0 
(5.0) 
6.0 
(8.5) 
2.8 
(2.9) 
3.8 
(3.6) 
1.8 
(0.9) 
3.8 
(3.8) 
7.8 
(9.3) 
3.1 
(2.1) 
6.4 
(8.7) 
3.1 
(2.7) 
6.5 
(11.7) 
2.96 
(3.3) 
follow up time 
(years) 
4.8 
(3.9) 
2.0 
(1.7) 
6.7 
(3.2) 
3.2 
(2.8) 
4.0 
(4.6) 
2.2 
(1.7) 
3.0 
(3.6) 
6.7 
(3.2) 
3.5 
(1.7) 
3.5 
(1.7) 
3.1 
(2.8) 
4.0 
(3.3) 
0.4 
(1.4) 
 
Values are expressed as n (%) or mean (SD). 
PD: Parkinson’s disease, DLB: dementia with Lewy bodies, PAF: pure autonomic failure, MSA: multiple system atrophy, PSP: progressive supranuclear palsy, CBD: corticobasal degeneration, VaP: vascular parkinsonism, 
Drug-induced: drug-induced parkinsonism, ET: essential tremor, AD/MCI: Alzheimer’s disease/mild cognitive impairment, MIBG: metaiodobenzylguanidine.   
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Table 2 Characteristics of Parkinson’s disease patients 
 
      PD (n = 272) 
Male (%) 119 
 
(43.8%) 
Age at onset: years       62.2 
 
(12.8) 
Age at MIBG test: years       66.4 
 
(11.8) 
Disease duration: years  4.1 
 
(5.1) 
Follow-up time: years                                                            4.8 
 
(3.9)
Initial symptoms 
   
     Motor symptoms 
   
         Gait disturbance/postural instability 69 
 
(25.4%) 
         Rigidity 48 
 
(17.7%) 
         Tremor 127 
 
(46.7%) 
         Bradykinesia 30 
 
(11.0%)     
     Non-motor symptoms 
   
         Dementia 2 
 
(0.01%) 
         Orthostatic hypotension 2 
 
(0.01%) 
         Depression 10 
 
(0.04%) 
         Constipation 1 
 
(0.004%) 
         Urinary disturbance 0 
 
(0%) 
         Hallucination 0 
 
(0%) 
         RBD 2 
 
(0.01%) 
         Others 1 
 
(0.004%) 
         Undetermined 1 
 
(0.004%)     
Symptoms at MIBG test 
   
     Motor symptoms 
   
         Gait disturbance/postural instability 136 
 
(50.0%) 
         Rigidity 189 
 
(69.5%) 
         Tremor 56 
 
(20.6%) 
         Bradykinesia 195 
 
(71.7%)     
     Non-motor symptoms 
   
         Dementia 14 
 
(5.2%) 
         Orthostatic hypotension 13 
 
(4.8%) 
         Depression 28 
 
(10.3%) 
         Constipation 126 
 
(46.3%) 
         Urinary disturbance 57 
 
(21.0%) 
         Hallucination 14 
 
(5.2%) 
         RBD 40 
 
(14.7%) 
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Table 2 (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed as n (%) or mean (SD). 
RBD: rapid eye movement sleep behavior disorder. 
MIBG: metaiodobenzylguanidine. 
Anti-parkinsonian medications at MIBG test    
         Levodopa  116 
 
(42.7%) 
         Dose of levodopa: mg  334.5 
 
(155.3)  
         Dopamine agonist   74  (27.2%) 
Hoehn & Yahr stage    
         0 1  (0.4%) 
         1 52  (19.1%) 
         2 62  (22.8%) 
         3 106  (39.0%) 
         4 17  (6.3%) 
         5 2  (0.7%) 
undetermined 32  (11.8%) 
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Table 3 Characteristics of PD and non-PD patients according to disease duration 
 PD (n = 272)  non-PD (n = 169) 
 0 < Duration ≤ 3 Duration > 3  0 < Duration ≤ 3 Duration > 3 
n  155 117  96 73 
Males  68 (43.9%) 51 (43.6%)  47 (49.0%) 35 (48.0%) 
Age at onset (years) 65.3 ± 12.3 58.2 ± 12.5  68.8 ± 10.6 63.1 ±13.1 
Age at MIBG test (years) 66.4 ± 12.3 66.4 ± 11.1  70.0 ± 10.7 70.1 ± 10.4 
Disease duration (years) 1.0 ± 0.7 8.2 ± 5.6  1.2 ± 0.7 7.0 ± 7.1 
Hoehn & Yahr 0 1 (0.6%) 0    
1 32 (20.6%) 20 (17.1%)    
2 41 (26.5%) 21 (17.9%)    
 3 67 (43.2%) 39 (33.3%)    
4 2 (1.3%) 15 (12.8%)    
5 0 2 (1.7%)    
undetermined 12 (7.7%) 20 (17.1%)    
Hoehn & Yahr  2.3 ± 0.8 2.6 ± 1.0    
Early H/M < 2.0 100 (64.5%) 102 (87.2%)  12 (13.0%) 18 (24.7%) 
Delayed H/M < 2.0 103 (66.5%) 101 (86.3%)  8 (8.0%) 19 (26.0%) 
Values are expressed as n (%) or mean ± SD. 
Non-PD patients included MSA, PSP, CBD, VaP, drug-induced, unclassified, ET, AD/MCI, and others. 
PD: Parkinson’s disease, DLB: dementia with Lewy bodies, PAF: pure autonomic failure, MSA: multiple system atrophy, PSP: progressive 
supranuclear palsy, CBD: corticobasal degeneration, VaP: vascular parkinsonism, Drug-induced: drug-induced parkinsonism, Unclassified: 
unclassified parkinsonian syndrome, ET: essential tremor, AD/MCI: Alzheimer’s disease/mild cognitive impairment, MIBG: metaiodobenzylguanidine.
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Table 4 Clinical symptoms and early and delayed H/M ratio 
 Early H/M ratio 
 
  
   
Delayed H/M ratio 
 
  
  
 
 
Yes 
 
No 
   
Yes 
 
No 
  
 
 
Mean (95% CI) 
 
Mean (95% CI) Difference (95% CI) p value 
 
Mean (95% CI) 
 
Mean (95% CI)   Difference (95% CI)  p value  
Initial symptoms 
           
 
     Motor symptoms 
           
 
           Gait disturbance/postural instability 1.73 (1.65 to 1.82) 
 
1.75 (1.70 to 1.79) 0.02 (–0.08 to 0.11) 0.758 
 
1.59 (1.53 to 1.66) 
 
1.62 (1.51 to 1.73) –0.03 (–0.16 to 0.10) 0.686  
           Rigidity 1.64 (1.54 to 1.74) 
 
1.76 (1.72 to 1.81) 0.13 (0.01 to 0.24) 0.031 * 1.43 (1.30 to 1.56) 
 
1.64 (1.58 to 1.70) 0.21 (0.06 to 0.35) 0.006 * 
           Tremor 1.78 (1.72 to 1.84) 
 
1.71 (1.65 to 1.76) –0.08 (–0.16 to 0.01) 0.078 
 
1.65 (1.57 to 1.74) 
 
1.55 (1.48 to 1.63) –0.10 (–0.21 to 0.01) 0.075  
           Bradykinesia 1.69 (1.56 to 1.82) 
 
1.75 (1.70 to 1.79) 0.06 (–0.08 to 0.20) 0.379 
 
1.55 (1.38 to 1.72) 
 
1.61 (1.55 to 1.67) 0.06 (–0.12 to 0.24) 0.512  
            
 
Symptoms at MIBG test 
           
 
     Motor symptoms 
           
 
           Gait disturbance/postural instability 1.72 (1.66 to 1.78) 
 
1.76 (1.70 to 1.82) 0.04 (–0.05 to 0.12) 0.389 
 
1.56 (1.48 to 1.63) 
 
1.65 (1.57 to 1.72) 0.09 (–0.02 to 0.20) 0.111  
           Rigidity 1.75 (1.70 to 1.80) 
 
1.72 (1.65 to 1.80) –0.03 (–0.12 to 0.07) 0.565 
 
1.63 (1.56 to 1.70) 
 
1.53 (1.43 to 1.63) –0.10 (–0.22 to 0.02) 0.117  
           Tremor 1.68 (1.59 to 1.77) 
 
1.76 (1.71 to 1.81) 0.08 (–0.03 to 0.18) 0.137 
 
1.49 (1.37 to 1.61) 
 
1.63 (1.57 to 1.69) 0.14 (0.002 to 0.28) 0.047 * 
           Bradykinesia 1.75 (1.70 to 1.80) 
 
1.73 (1.65 to 1.81) –0.02 (–0.11 to 0.08) 0.743 
 
1.60 (1.54 to 1.67) 
 
1.59 (1.48 to 1.69) –0.02 (–0.14 to 0.11) 0.809  
            
 
     Non-motor symptoms 
           
 
           Dementia 1.62 (1.43 to 1.81) 
 
1.75 (1.70 to 1.79) 0.13 (–0.07 to 0.33) 0.193 
 
1.46 (1.21 to 1.71) 
 
1.61 (1.55 to 1.67) 0.15 (–0.11 to 0.41) 0.250  
           OH 1.68 (1.48 to 1.87) 
 
1.74 (1.70 to 1.79) 0.07 (–0.13 to 0.27) 0.513 
 
1.38 (1.13 to 1.64) 
 
1.61 (1.55 to 1.67) 0.23 (–0.03 to 0.49) 0.088  
           Depression 1.72 (1.59 to 1.86) 
 
1.74 (1.70 to 1.79) 0.02 (–0.12 to 0.16) 0.788 
 
1.55 (1.38 to 1.72) 
 
1.61 (1.55 to 1.67) 0.06 (–0.13 to 0.24) 0.557  
           Constipation 1.64 (1.58 to 1.70) 
 
1.83 (1.77 to 1.88) 0.19 (0.10 to 0.27) < 0.001 * 1.49 (1.41 to 1.57) 
 
1.70 (1.62 to 1.77) 0.21 (0.10 to 0.32) < 0.001 * 
           Urinary disturbance 1.63 (1.54 to 1.73) 
 
1.77 (1.72 to 1.82) 0.14 (0.03 to 0.24) 0.011 * 1.46 (1.34 to 1.59) 
 
1.64 (1.57 to 1.70) 0.17 (0.04 to 0.31) 0.013 * 
           Hallucination 1.64 (1.45 to 1.83) 
 
1.75 (1.70 to 1.79) 0.11 (–0.09 to 0.30) 0.274 
 
1.47 (1.23 to 1.72) 
 
1.61 (1.55 to 1.66) 0.13 (–0.12 to 0.39) 0.303  
           RBD 1.60 (1.49 to 1.71) 
 
1.77 (1.72 to 1.81) 0.17 ( 0.05 to 0.29) 0.005 * 1.43 (1.29 to 1.58) 
 
1.63 (1.57 to 1.69) 0.20 (0.04 to 0.35) 0.015 * 
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Table 4 (continued) 
CI: confidence interval, OH: orthostatic hypotension, RBD: rapid eye movement sleep behavior disorder, * p < 0.05. 
 
